Vertex demonstrates a methodical approach to building its post-cystic fibrosis pipeline. Under its current CEO, the company started with sub-$1 billion deals to "get their feet wet" before escalating to larger acquisitions like the $4.9B Alpine deal and now the $10B Crenetics deal, indicating a carefully managed increase in scale and risk.

The nature of biopharma M&A changed dramatically in a year. After a period with no deals over $5 billion, there are now seven or eight such transactions, reflecting a pivot by large pharma to acquire de-risked assets with large market potential to offset looming patent expirations.

Eli Lilly's deal chief revealed that even premium acquisition offers are frequently rebuffed by public biotech companies without negotiation. This highlights a significant valuation gap where biotech boards believe their assets are worth far more than what even well-capitalized buyers like Lilly are willing to pay, stalling potential M&A activity.

Contrary to seeking fully de-risked assets, pharmaceutical companies often prefer acquiring companies with some remaining clinical risk. This strategy allows them to leverage unique insights on early data to acquire assets at a better valuation, creating an opportunity for outsized returns before the value is obvious to others.

After years of focusing on de-risked late-stage products, the M&A market is showing a renewed appetite for risk. Recent large deals for early-stage and platform companies signal a return to an era where buyers gamble on foundational science.

The acquisition gives Vertex an approved drug, a late-stage pipeline, and a foothold in rare endocrine diseases. This move is a strategic diversification away from its core cystic fibrosis business, aiming for a multi-billion dollar peak sales opportunity in a new therapeutic area.

A successful acquisition strategy goes beyond the highest bid. It involves 'thinking like the molecule'—evaluating which buyer has the specific expertise, capabilities, and cultural alignment to best steward the asset's development. This reframes M&A from a financial transaction to a decision about the asset's future.

The "takeout candidate" thesis often fails because corporate development teams at large firms won't risk their careers on optically cheap but unprofitable assets. They prefer to overpay for proven, de-risked companies later, making cheapness a poor indicator of an impending acquisition.

With patent cliffs looming and mature assets acquired, large pharmaceutical companies are increasingly paying billion-dollar prices for early-stage and even preclinical companies. This marks a significant strategic shift in M&A towards accepting higher risk for earlier innovation.